BioPharmSignal logoBioPharmSignal

Biotech News

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion (CYCN)CyclerionCompany update

Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease

Related news

TEVATeva Pharmaceutical Industries2026-08-31 20:07 EST

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

GANXGain Therapeutics2026-09-29 21:50 EST

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

AXSMAxsome2026-09-17 11:00 EST

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

BTAIBioXcel2026-08-28 10:00 EST

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

BCLIBrainstorm Cell Therapeutics Inc.2026-08-14 20:00 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

NBIXNeurocrine Biosciences2026-10-22 20:05 EST

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

CGTXCognition Therapeutics2026-10-22 10:00 EST

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

NBIXNeurocrine Biosciences2026-10-20 12:30 EST

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

View all latest news

Cyclerion

Cyclerion was a biotechnology company focused on cyclic nucleotide biology and central nervous system or vascular-related disease programs before becoming a historical ticker. Its story reflected the challenge of turning a mechanistic platform into a durable drug franchise.

Recent company news

CYCNCyclerion2026-04-01 11:05 EST

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

CYCNCyclerion2026-02-17 12:00 EST

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

CYCNCyclerion2026-01-05 21:01 EST

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

CYCNCyclerion2025-09-23 20:01 EST

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

CYCNCyclerion2024-12-17 13:08 EST

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Stock data

Close
23.52 USD
Market cap
13.08M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States